We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Will Biogen (BIIB) Succeed in Beating Q2 Earnings Estimates?
Read MoreHide Full Article
We expect Biogen, Inc. (BIIB - Free Report) to beat expectations when it reports second-quarter 2022 results on Jul 20, before market open. In the last reported quarter, the company delivered an earnings surprise of 17.91%.
The company’s earnings beat estimates in three of the last four quarters, while missing expectations in one. The company has a four-quarter earnings surprise of 5.86%, on average.
Biogen’s stock has declined 9.6% this year so far compared with a decrease of 20.5% for the industry.
Image Source: Zacks Investment Research
Factors to Consider
Biogen’s sales in the second quarter are likely to have been hurt by lower sales of Tecfidera and Spinraza.
Biogen’s multiple sclerosis revenues have been declining since the past few quarters. It is unlikely that multiple sclerosis sales have improved in the second quarter.
Among Biogen’s MS drugs, sales of Tecfidera are likely to have declined steeply, hurt by the launch of multiple generics products in the United States. Tecfidera generics are also expected to be launched in Europe in the second quarter. It remains to be seen if generics were launched in Europe and hurt ex-U.S sales from the drug.
Sales of another MS drug, Tysabri may have benefited from volume increases and patient growth, despite increased competitive pressure and price reductions in certain European markets.
The Zacks Consensus Estimate for sales of Tecfidera in the second quarter is pegged at $341 million, while that for Tysabri is $509 million.
Sales volumes of another MS drug Vumerity are likely to have increased, driven by demand growth including the launch in Europe. The Zacks Consensus Estimate for Vumerity is $139 million.
Biogen receives royalties on U.S. sales of Roche’s (RHHBY - Free Report) MS drug, Ocrevus, which is also expected to have contributed to the top line. The Zacks Consensus Estimate for Ocrevus royalties is $270 million.
Roche’s Ocrevus (ocrelizumab) was approved for the treatment of relapsing MS (RMS) and primary progressive MS (PPMS) in March 2017
Revenues from Biogen’s share of Roche’s drugs, Rituxan and Gazyva are also likely to have declined in the quarter due to biosimilar competition for Rituxan.
Increased competition in the United States is likely to have hurt sales of Biogen’s spinal muscular atrophy drug, Spinraza, in the United States. However, in the first quarter, Biogen had said that Spinraza new patient starts were at the highest levels in over two years, with a continued slowdown in discontinuations. It remains to be seen if this positive trend continued in the second quarter
Outside the United States, sales of Spinraza might have been hurt due to competition and currency headwinds. The Zacks Consensus Estimate for sales of Spinraza is $437 million.
Biogen is likely not to record any sales from the new Alzheimer’s drug, Aduhelm, in the second quarter. After the Centers for Medicare & Medicaid Services (“CMS”) denied all Medicare beneficiaries access to Aduhelm, in its final NCD decision, Biogen decided to substantially wind down commercial operations for Aduhelm, retaining only minimal resources to manage patients’ access programs.
Biosimilars revenues may have benefited from volume increase, which is likely to have been offset by pricing pressure and currency headwinds. The Zacks Consensus Estimate for sales of biosimilars is $200 million.
The reduction in revenues from Tecfidera and Rituxan, both high-margin products, is expected to have lowered Biogen’s gross margin in the second quarter.
Following its failure with Aduhelm, Biogen announced a set of near-term operational priorities to drive renewed growth and value creation over time. The initiatives are expected to have resulted in lower SG&A costs in the second quarter.
Earnings Whispers
Our proven model predicts an earnings beat for Biogen in the to-be-reported quarter. A stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for a likely positive surprise. This is the case here, as elaborated below.
Earnings ESP: Biogen’s Earnings ESP is +2.87% as the Most Accurate Estimate of $4.21 is higher than the Zacks Consensus Estimate of $4.09. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Biogen has a Zacks Rank #3
Other Stocks to Consider
Here are some large drug/biotech stocks that also have the right combination of elements to beat. Here are some large drug stocks that also have the right combination of elements to beat on earnings this time around:
Merck’s stock has risen 23.9% this year so far. Merck topped earnings estimates in three of the last four quarters. Merck has a four-quarter earnings surprise of 13.42%, on average. MRK is scheduled to release its second-quarter 2022 results on Jul 28.
BioNTech (BNTX - Free Report) has an Earnings ESP of +1.99% and a Zacks Rank #2.
BioNTech’s stock has plunged 40.1% in the past year. BioNTech topped earnings estimates in all the last four quarters. BioNTech has a four-quarter earnings surprise of 56.87%, on average.
Image: Bigstock
Will Biogen (BIIB) Succeed in Beating Q2 Earnings Estimates?
We expect Biogen, Inc. (BIIB - Free Report) to beat expectations when it reports second-quarter 2022 results on Jul 20, before market open. In the last reported quarter, the company delivered an earnings surprise of 17.91%.
The company’s earnings beat estimates in three of the last four quarters, while missing expectations in one. The company has a four-quarter earnings surprise of 5.86%, on average.
Biogen Inc. Price and EPS Surprise
Biogen Inc. price-eps-surprise | Biogen Inc. Quote
Biogen’s stock has declined 9.6% this year so far compared with a decrease of 20.5% for the industry.
Image Source: Zacks Investment Research
Factors to Consider
Biogen’s sales in the second quarter are likely to have been hurt by lower sales of Tecfidera and Spinraza.
Biogen’s multiple sclerosis revenues have been declining since the past few quarters. It is unlikely that multiple sclerosis sales have improved in the second quarter.
Among Biogen’s MS drugs, sales of Tecfidera are likely to have declined steeply, hurt by the launch of multiple generics products in the United States. Tecfidera generics are also expected to be launched in Europe in the second quarter. It remains to be seen if generics were launched in Europe and hurt ex-U.S sales from the drug.
Sales of another MS drug, Tysabri may have benefited from volume increases and patient growth, despite increased competitive pressure and price reductions in certain European markets.
The Zacks Consensus Estimate for sales of Tecfidera in the second quarter is pegged at $341 million, while that for Tysabri is $509 million.
Sales volumes of another MS drug Vumerity are likely to have increased, driven by demand growth including the launch in Europe. The Zacks Consensus Estimate for Vumerity is $139 million.
Biogen receives royalties on U.S. sales of Roche’s (RHHBY - Free Report) MS drug, Ocrevus, which is also expected to have contributed to the top line. The Zacks Consensus Estimate for Ocrevus royalties is $270 million.
Roche’s Ocrevus (ocrelizumab) was approved for the treatment of relapsing MS (RMS) and primary progressive MS (PPMS) in March 2017
Revenues from Biogen’s share of Roche’s drugs, Rituxan and Gazyva are also likely to have declined in the quarter due to biosimilar competition for Rituxan.
Increased competition in the United States is likely to have hurt sales of Biogen’s spinal muscular atrophy drug, Spinraza, in the United States. However, in the first quarter, Biogen had said that Spinraza new patient starts were at the highest levels in over two years, with a continued slowdown in discontinuations. It remains to be seen if this positive trend continued in the second quarter
Outside the United States, sales of Spinraza might have been hurt due to competition and currency headwinds. The Zacks Consensus Estimate for sales of Spinraza is $437 million.
Biogen is likely not to record any sales from the new Alzheimer’s drug, Aduhelm, in the second quarter. After the Centers for Medicare & Medicaid Services (“CMS”) denied all Medicare beneficiaries access to Aduhelm, in its final NCD decision, Biogen decided to substantially wind down commercial operations for Aduhelm, retaining only minimal resources to manage patients’ access programs.
Biosimilars revenues may have benefited from volume increase, which is likely to have been offset by pricing pressure and currency headwinds. The Zacks Consensus Estimate for sales of biosimilars is $200 million.
The reduction in revenues from Tecfidera and Rituxan, both high-margin products, is expected to have lowered Biogen’s gross margin in the second quarter.
Following its failure with Aduhelm, Biogen announced a set of near-term operational priorities to drive renewed growth and value creation over time. The initiatives are expected to have resulted in lower SG&A costs in the second quarter.
Earnings Whispers
Our proven model predicts an earnings beat for Biogen in the to-be-reported quarter. A stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for a likely positive surprise. This is the case here, as elaborated below.
Earnings ESP: Biogen’s Earnings ESP is +2.87% as the Most Accurate Estimate of $4.21 is higher than the Zacks Consensus Estimate of $4.09. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Biogen has a Zacks Rank #3
Other Stocks to Consider
Here are some large drug/biotech stocks that also have the right combination of elements to beat. Here are some large drug stocks that also have the right combination of elements to beat on earnings this time around:
Merck (MRK - Free Report) has an Earnings ESP of +7.18% and a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Merck’s stock has risen 23.9% this year so far. Merck topped earnings estimates in three of the last four quarters. Merck has a four-quarter earnings surprise of 13.42%, on average. MRK is scheduled to release its second-quarter 2022 results on Jul 28.
BioNTech (BNTX - Free Report) has an Earnings ESP of +1.99% and a Zacks Rank #2.
BioNTech’s stock has plunged 40.1% in the past year. BioNTech topped earnings estimates in all the last four quarters. BioNTech has a four-quarter earnings surprise of 56.87%, on average.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.